Member Directory - TB Working Group

Chair: Susan Swindells

Objectives:

  • Guide product development and identify knowledge gaps requiring further research and resources for the prevention and treatment of tuberculosis (TB). Our goal is to identify the most promising drug candidates for development as long-acting/extended release (LA/ER) formulations.
  • Promote the development of LA/ER approaches for TB by building on previous modelling and preclinical work to evaluate novel long-acting formulations of TB drugs.
  • Develop additional applications to understand if in silico modelling can predict important drug-drug interactions involving LA/ER formulations, a particularly relevant issue for HIV and TB drugs where rifamycins are the source of many complex and significant interactions. Models will also be improved to provide dosing strategies for infants, children, adolescents, and pregnant women.

Interested in joining?
Please submit your request and your CV to Ana Cervantes. Acceptance requires a written nomination from a TB Working Group member and majority approval.

Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA.

Conflict of Interest: Dr. Swindells reports research grants to her institution from ViiV Healthcare.

Nicole Ammerman is a Research Associate in the Department of Medicine, Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. She has a PhD in Microbiology and Immunology from the University of Maryland School of Medicine and an ScM in Epidemiology from the Johns Hopkins University Bloomberg School of Public Health. Her research focuses on the experimental chemotherapy of tuberculosis and nontuberculous mycobacterial diseases.

Richard E. Chaisson, MD, is Professor of Medicine, Epidemiology, and International Health at Johns Hopkins University and Director of the Johns Hopkins Center for TB Research and the Center for AIDS Research.

Conflict of Interest: My spouse owns stock in Merck.  I have consulted for Sanofi.

Tine has a PhD in Veterinary Sciences from the University of Ghent, Belgium and earned her MBA in Pharmaceutical Management from Drexel LeBow College of Business. She has additional Masters degrees in Biology and Teaching. Tine is Compound Development Team Lead for Tuberculosis at Johnson & Johnson Global Public Health.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Dr. Flexner has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Algernon Pharmaceuticals; Gilead; Merck; Mylan Pharmaceuticals; ViiV Healthcare. 

Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y. After completing her postdoctoral research fellowship in the department of Immunology at Smith Kline, she joined the antiviral research group as a Senior Research Biochemist at Merck in 1989.

Dr. Nuermberger is an Associate Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials.

David has >20 years of infectious disease drug discovery experience with a focus on HIV-1 and HCV. In 2011 he was given the responsibility of directing Merck’s Neglected Tropical Disease discovery efforts that includes tuberculosis, macrofilaria, Chagas, Leishmania, malaria and Ebola.

Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. 

Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare

Dr. Chuck Peloquin received his BS in Pharmacy from the University of Connecticut and his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. 

Manuele Piccolis joined the Medicine Patent Pool as Scientific Manager for Infectious Diseases in March 2020. He holds a PhD in Life Sciences from the University of Geneva and he has an extensive experience in metabolism. Before joining MPP Manuele worked extensively on lipid metabolism at the Gladstone Institutes (CA), Harvard HSPH (MA) and the EPFL (CH).

Dr. Podany is currently an Assistant Professor in the department of pharmacy practice at the University of Nebraska Medical Center.

Dr. Rangaka is an Associate Professor within the Institute of Global Health, University College London (UCL), United Kingdom. She is also affiliated to the MRC Clinical Trials Unit at UCL and is an honorary Associate Professor at the University of Cape Town (UCT), South Africa.

Bart Remmerie, Chem. Eng., graduated as a bio-engineer and as environmental engineer at Ghent University, Belgium. He started at Janssen (Bioanalysis) in 1994 and joined the Clinical Pharmacology group in 2006, initially primarily working on neuroscience projects, and more recently also on anti-infectives. 

Kimberly Scarsi is an Associate Professor at the University of Nebraska Medical Center’s (UNMC) College of Pharmacy. Her research program focuses on optimizing pharmacologic therapies for persons living with HIV, with an emphasis on global health and sex/gender related issues.

Dr Marco Siccardi graduated with an MSc in Clinical Biology (2006) at the University of Turin, Italy. He obtained his PhD at the University of Liverpool, Liverpool, UK (2011) focusing his research on molecular mechanisms influencing drug distribution and predictors of exposure in patients. He was recently appointed as a Lecturer in Pharmacology across the faculties of Health & Life Sciences and Science & Engineering at the University of Liverpool.